The present invention relates to an extemporaneous product for the preparation of dermatological and/or cosmetic compositions, this product comprising, on the one hand, one or several active substances and on the other, a universal base allowing such active substance or substances to be solubilised and comprising at least one oil rich in omega-3, water, glycerine, an alcohol other than glycerine, and emulsifier and a biomimetic peptide.

The present invention relates to an extemporaneous product for the preparation of dermatological and/or cosmetic compositions, this product comprising, on the one hand, one or several active substances and on the other, a universal base allowing such active substance or substances to be solubilised and comprising at least one oil rich in omega-3, water, glycerine, an alcohol other than glycerine, and emulsifier and a biomimetic peptide.

Hand sanitizers are provided with improved aesthetics and skin-conditioning effects, such that healthcare workers and others subject to high frequency hand hygiene requirements are encouraged to comply with said requirements. The hand sanitizers provide excellent antimicrobial efficacy and skin conditioning benefits that actually increase with increased frequency of use. The sanitizing compositions are hydroalcoholic, and contain a synergistic combination of skin-conditioning agents.

Hand sanitizers are provided with improved aesthetics and skin-conditioning effects, such that healthcare workers and others subject to high frequency hand hygiene requirements are encouraged to comply with said requirements. The hand sanitizers provide excellent antimicrobial efficacy and skin conditioning benefits that actually increase with increased frequency of use. The sanitizing compositions are hydroalcoholic, and contain a synergistic combination of skin-conditioning agents.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities.

The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities.